AI 中文总结
CoMERC是一种故障封闭的多层准蒙特卡洛控制器，通过联合控制四个误差端点，在合成体模中实现保守剂量重映射的有限样本误差控制，并降低生产样本工作量。
AI 中文摘要
保守剂量重映射可以通过在非匹配网格间传输质量和沉积能量来表述，但固定的高采样计算对简单和困难情况使用相同的工作量。我们开发了共形多分辨率误差控制（CoMERC），一种故障封闭的多层准蒙特卡洛（QMC）控制器，用于在具有已知形变的固定分段常数源模型中控制参考相对目标单元分配误差。在探针层级4和候选层级8和16下评估了两个随机嵌套重复。四个端点被联合控制：参考质量加权的全局、高梯度和密度梯度阈值均方根误差，以及合格单元的最大绝对误差。一个分裂共形乘数从240个合成案例中校准，冻结，并在来自同一生成器的400个独立案例和来自预设偏移生成器的120个案例上评估。在主要集合中，联合覆盖率为394/400（98.50%；单侧95%下限，97.06%），388/400案例（97.00%；下限，95.18%）获得输出，0/388释放的输出超过任何容差（单侧95%上限，0.769%）。最终动作为190个案例选择层级8，198个案例选择层级16，12个案例选择弃权（不执行）。冻结策略意味着与始终运行两个随机重复至层级16相比，平均相对生产样本工作量为0.5844；预设的95百分位自助法上限为0.6194。所有七个主要门控通过。在偏移生成器集合中，113/120案例被释放，一个释放的输出超过容差。CoMERC在锁定的合成总体中提供了边际有限样本误差控制和较低的建模生产样本工作量，但不提供患者级别、配准级别、条件释放或临床安全性验证。
英文摘要
Conservative dose remapping can be formulated by transporting mass and deposited energy across nonmatching grids, but fixed sampling uses the same number of points per active source cell regardless of case difficulty. We developed conformal multiresolution error control (CoMERC), a fail-closed multilevel quasi-Monte Carlo (QMC) controller for reference-relative target-cell allocation error in a fixed piecewise-constant source model with known deformation. Two randomized nested replicates were evaluated at a probe level of 4 and candidate levels of 8 and 16. Four endpoints were controlled jointly: reference-mass-weighted global, high-gradient, and density-gradient-threshold root-mean-square error, plus eligible-cell maximum absolute error. A split-conformal multiplier was calibrated from 240 synthetic cases, frozen, and evaluated on 400 independent cases from the same generator and 120 cases from a prespecified shifted generator. In the primary set, joint coverage was 394/400 (98.50%; one-sided 95% lower limit, 97.06%), 388/400 cases (97.00%; lower limit, 95.18%) received an output, and 0/388 released outputs exceeded any tolerance (one-sided 95% upper limit, 0.769%). Final actions were level 8 for 190 cases, level 16 for 198, and ABSTAIN for 12. The mean of the case-normalized, policy-implied production-sample ratios was 0.5844, with each case normalized to always running both randomized replicates through level 16; the prespecified 95th-percentile bootstrap upper limit was 0.6194. All seven primary gates passed. In the shifted-generator set, 113/120 cases were released and one released output exceeded a tolerance. CoMERC provided marginal finite-sample error control and lower modeled production-sample work in the locked synthetic population, but not patient-level, registration-level, conditional-on-release, or clinical safety validation.
